Abbonarsi

Plasma proteomics and lung function in four community-based cohorts - 12/02/21

Doi : 10.1016/j.rmed.2020.106282 
Andreas Rydell a, b, Christoph Nowak a, Christer Janson c, Karin Lisspers d, Björn Ställberg d, David Iggman b, f, Jerzy Leppert h, Pär Hedberg h, i, Johan Sundström g, j, Erik Ingelsson k, l, Lars Lind g, Johan Ärnlöv a, b, e,
a Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institute, Huddinge, Sweden 
b Region Dalarna, Falun, Sweden 
c Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden 
d Department of Public Health and Caring Science, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden 
e School of Health and Social Sciences, Dalarna University, Falun, Sweden 
f Unit for Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden 
g Department of Medical Sciences, Clinical Epidemiology, Uppsala University, Uppsala, Sweden 
h Center for Clinical Research, Region Västmanland-Uppsala University, Hospital of Västmanland, Västerås, Sweden 
i Department of Clinical Physiology, Hospital of Västmanland, Västerås, Sweden 
j The George Institute for Global Health, University of New South Wales, Sydney, Australia 
k Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA 
l Stanford Cardiovascular Institute, Stanford University, Stanford, CA, 94305, USA 

Corresponding author. Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.Division of Family Medicine and Primary CareDepartment of NeurobiologyCare Sciences and SocietyKarolinska InstitutetHuddingeSweden

Abstract

Background

Underlying mechanism leading to impaired lung function are incompletely understood.

Objectives

To investigate whether protein profiling can provide novel insights into mechanisms leading to impaired lung function.

Methods

We used four community-based studies (n = 2552) to investigate associations between 79 cardiovascular/inflammatory proteins and forced expiratory volume in 1 s percent predicted (FEV1%) assessed by spirometry. We divided the cohorts into discovery and replication samples and used risk factor-adjusted linear regression corrected for multiple comparison (false discovery rate of 5%). We performed Mendelian randomization analyses using genetic and spirometry data from the UK Biobank (n = 421,986) to assess causality.

Measurements and main results

In cross-sectional analysis, 22 proteins were associated with lower FEV1% in both the discovery and replication sample, regardless of stratification by smoking status. The combined proteomic data cumulatively explained 5% of the variation in FEV1%. In longitudinal analyses (n = 681), higher plasma levels of growth differentiation factor 15 (GDF-15) and interleukin 6 (IL-6) predicted a more rapid 5-year decline in lung function (change in FEV1% per standard deviation of protein level −1.4, (95% CI, −2.5 to −0.3) for GDF-15, and -0.8, (95% CI, −1.5 to −0.2) for IL-6. Mendelian randomization analysis in UK-biobank provided support for a causal effect of increased GDF-15 levels and reduced FEV1%.

Conclusions

Our combined approach identified GDF-15 as a potential causal factor in the development of impaired lung function in the general population. These findings encourage additional studies evaluating the role of GDF-15 as a causal factor for impaired lung function.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

Protein profiling may provide new insights into mechanisms for impaired lung function.
Twenty-two proteins were cross-sectionally associated with FEV1% in four cohorts.
Mendelian randomization analysis provided support for a causal effect of GDF-15.
GDF-15 could be a suitable target for interventions to prevent lung function decline.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : FEV1, Protein expression, Proteomics, Mendelian randomization

Abbreviations : PIVUS, POEM, SAVa, PADVa, BMI, COPD, CVD, FEV1, GWAS, MR


Mappa


© 2020  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 176

Articolo 106282- gennaio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Lung function is associated with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in school-aged children
  • Suneela Zaigham, Magnus Dencker, Magnus K. Karlsson, Ola Thorsson, Per Wollmer
| Articolo seguente Articolo seguente
  • Measuring vital capacity in amyotrophic lateral sclerosis: Effects of interfaces and reproducibility
  • Giulia Michela Pellegrino, Giuseppe Francesco Sferrazza Papa, Stefano Centanni, Massimo Corbo, David Kvarnberg, Martin J. Tobin, Franco Laghi

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.